-+ 0.00%
-+ 0.00%
-+ 0.00%
The Zhitong Finance App learned that neladalkib, a lung cancer drug owned by GSK.US (GSK.US), was approved for marketing by the US Food and Drug Administration (FDA), providing new treatment options for patients whose condition is still progressing after receiving ALK targeted treatment, further verifying the strategic value of the British pharmaceutical company's previous acquisition of biotech company Nuvalent.
Share
Listen to the news
The Zhitong Finance App learned that neladalkib, a lung cancer drug owned by GSK.US (GSK.US), was approved for marketing by the US Food and Drug Administration (FDA), providing new treatment options for patients whose condition is still progressing after receiving ALK targeted treatment, further verifying the strategic value of the British pharmaceutical company's previous acquisition of biotech company Nuvalent.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending